Physician profile
James Weed
NPI 1770968596
$343.56
in general payments reported to CMS, 2019-2025
7 companies · $78.29 in 2025
The $78.29 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $83.83 · 2023: $43.53 · 2024: $138 · 2025: $78.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $235 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $234.73 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $171.22 | 2021-2024 | Farxiga |
| Novo Nordisk INC | $49.43 | 2025 | |
| Abbvie INC. | $47.97 | 2024-2025 | |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Lilly USA, LLC | $18.53 | 2023 | Mounjaro |
| Abbott Laboratories | $17.54 | 2024 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $13.87 | 2025 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Weed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.